News
Bio-tech firm develops 3D printed replacement cornea for human eyes
After successfully transplanting the first 3D-printed cornea in an animal, North Carolina company Precise Bio has recently announced the launch of a dedicated business for creating marketable, 3D-printed products for human eyes. Founded by scientists from the Wake Forest Institute of Regenerative Medicine, this company is developing bio-fabrication printers that can restore cells, tissues, and organs. Their proprietary technology, a 4D bio-printing platform, is said to resolve existing limitations presented by other bioprinters to enable more complex tissues to be engineered for transplants and treatments. By focusing on developing marketable products for the eye, the company aims to achieve rapid advancement in its field and move to overhaul the whole organ transplant system.
A cornea transplant with sutures still visible. | Credit: National Institutes for Health, National Eye Institute
When a cornea is damaged by disease or injury, a replacement is often needed to restore vision. Transplant surgery using donated corneas is an available solution, however, it relies on a deceased donor. While the waiting list in the United States is nearly non-existent, other countries require longer wait times, some over a year, before one is available. The Eye Bank Association of America estimates that around 10 million people suffer from corneal blindness that could potentially be restored via transplant surgery. An artificially manufactured cornea would overcome supply limitations while also contributing to the knowledge base to develop more complex organs such as hearts and livers.
The cornea is the transparent layer covering the front part of the eye that, along with the lens, accounts for about two-thirds of the eye’s optical power. It does not contain blood vessels, making it a prime candidate for bioprinting, the field of 3D printing involving biological materials. Bioprinters differ from traditional 3D printers in ways that might not be surprising given their name. Instead of heated filament applied in layers on a plate to build an object, layers of cells and biocompatible materials are printed to form tissue. Along with a lack of blood vessels, the layered structure of the cornea also makes it well suited for bioprinting.
Precise Bio refers to its printing technique used for the corneas and other biomaterials as “4D” over the usual “3D” label due to the curing stage for the printed cells. The fourth dimension referred to is time needed, 10-14 days specifically, for the bio-printed cells and fibers to connect themselves together for biological operation in a bioreactor that keeps them warm for the duration. Aryeh Batt, Precise Bio’s CEO, summarized this step in an interview with IEEE Spectrum: “Essentially, the biology does the work, but you have to put them in the correct environment to make it happen.”
Initial animal safety studies for the corneal transplant have already been completed, and now the company must clear some additional hurdles to begin human testing. One of the major proofs for Precise Bio will be the demonstration of normal behavior of the bio-printed products. For example, during production using the 3D/4D printer, the printed cells grow rapidly into the form needed in a way that does not occur in a normal eye. The company will have to demonstrate in clinical studies how this process is controlled and stopped before transplant.
The field of 3D bioprinting is a research area receiving a significant amount of attention due to its potential for developments in tissue engineering, drug delivery, and cancer studies. In fact, hundreds of scientific articles were published on the topic this year alone. As with most new technology, however, the challenge of moving a development out of the laboratory and into the consumer marketplace is significant, but Precise Bio hopes to meet it head on with its new dedicated business.
For more on bioprinting, watch the below Tedx Talk by Dr. Sam Wadsworth of Aspect biosystems Ltd.
Tesla’s Supercharger Diner in Los Angeles dominated the company’s global usage rankings after just one year, proving the concept is more than just a one-off novelty location that will fade away.
The performance could incite the company to build more locations, something that CEO Elon Musk has hinted at for some time.
Tesla’s Supercharger Diner delivered 21.2 GWh of energy in its first year of operation, the company’s head of Charging, Max de Zegher, revealed on X. Of the top 10 most utilized Supercharger locations in Tesla’s global infrastructure, the Diner in Los Angeles was the most used by drivers, and it wasn’t particularly close:
Tesla Diner opened exactly 1 year ago. Inspiring that futuristic places like this exist.
It’s our highest usage Supercharger in the world: 21.2 GWh delivered in a year, 1.6k sessions/day.
Top 10 Superchargers by energy delivered: https://t.co/9YvJ8lw696 pic.twitter.com/koB3AUJHws
— Max (@MdeZegher) July 21, 2026
On its launch day one year ago, nobody was too sure what the Tesla Diner would be about. It seemed like an interesting concept, and considering it had been in the works for years, it was a highly anticipated launch that many were looking forward to.
Based on its success, we could see additional Diners with Superchargers built throughout the United States, and potentially beyond. Musk has said on several occasions that the company would be willing to bring the Diner idea to more markets.
Tesla makes major change at Supercharger Diner amid epic demand
Of the markets that Musk has mentioned, both Palo Alto and Austin have come to be perceived as ideal selections. However, there are no concrete plans as of now to build new Supercharger Diners anywhere; the location on Santa Monica Boulevard will remain the exclusive spot to pick up Tesla-inspired eats, at least for the time being.
Tesla short sellers won big following the company’s massive fall on Wall Street after it reported subpar Earnings on Wednesday.
Tesla short sellers collected about $4.12 billion in single-day profits on Thursday, according to Bloomberg. Shares fell as much as 15 percent during Thursday’s session. It closed as one of the worst days for Tesla on Wall Street in the past three years.
Investors sold off the stock after Tesla said it would aggressively direct its spending toward AI and its Optimus robot project. The company had record revenues, which were driven by one of the strongest quarters in terms of vehicle deliveries in company history.
However, it missed EPS estimates by reporting just $0.33, a far cry from the $0.53 analysts expected.
S3 Partners reported that about 3 percent of Tesla’s outstanding stock is sold short. Managing Director at S3, Ihor Dusaniwsky, provided the short seller’s potential profit, as well as another figure: shorts have likely had paper gains of $8.92 billion this year, as Tesla shares are down 30 percent in 2026.
Tesla (TSLA) Q2 2026 earnings results: miss on EPS, beat on revenue
Tesla has burned short sellers many times in the past, but the company’s latest Earnings Call was a chance for those skeptics to taste some payback. Although the company gave some very transparent information regarding future projects, the rollout of Robotaxi, Optimus, and Semi, many investors took their profits on Thursday.
Notable short sellers like Michael Burry have been transparent about their skepticism around Tesla shares. Burry just revealed three weeks ago that he had opened up a new short on the stock, stating he shorted Tesla shares at $416.22. “Happy it jumped back to this level,” he said in a blog post.
At the time of publication, Tesla shares were down about 3 percent and the stock was trading at $309.92.
Tesla’s long-standing saga regarding its door handles and a manual release has entered its latest chapter, and as a result, a big change is coming.
On Friday, the National Highway Traffic Safety Administration (NHTSA) denied Tesla’s petition that was seeking a defect investigation into roughly 180,000 Model 3 vehicles for an issue involving the emergency mechanical door release.
🚨 The NHTSA denied a petition from Tesla that would have thrown out concerns regarding its door handles.
NHTSA said Tesla’s petition did not present evidence of a safety-related defect warranting an investigation. The agency said a rulemaking process would be a better strategy. pic.twitter.com/j6PzUBM1mT
— TESLARATI (@Teslarati) July 24, 2026
NHTSA said that Tesla’s petition did not present evidence of a safety-related defect in the door handles or their emergency releases. Instead, the agency determined that it would rather solve the issue of the lack of labeling or location of emergency mechanical door releases and the federal safety rules that govern them.
Essentially, the NHTSA wants to create and enforce rules that would require automakers to make emergency door latch releases more clearly labeled in a car. Despite a Tesla having manual door releases on all four passenger doors, many people do not know they exist or how they work.
Tesla addresses door handle complaints with simple engineering fix
In recent times, Tesla has faced some criticism involving its door handles, specifically because some occupants have reported that they are unable to exit their vehicles after losing power. The door handles on a Tesla are electronically operated, but in the event that the 12V battery dies, there is a manual release that can be used.
The NHTSA only identified a single complaint involving the mechanical door releases: a 2022 Model 3 owner said the release was concealed and unlabeled after the vehicle lost power after a front-end collision. It has also already started to create a separate rulemaking process to make emergency door-egress systems more obvious.
It should be noted that all Teslas have mechanical emergency door releases, but they are placed in various locations as the vehicles have aged and been redesigned from year to year. Refer to the safety manual for your vehicle if you have any confusion about where the emergency releases are and how they work.
Tesla’s Supercharger Diner probably just secured more locations
Tesla short sellers win big after shares fall after earnings
